Longitudinal BCVA analysis of low- or high -dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham controlled, patient- and assessor masked clinical trial (RESTORE)

被引：0

|

作者：

Ho, Allen ^{[1
]}

机构：

[1] Wills Eye Hlth Syst, Ophthalmol, Philadelphia, PA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

2137

引用

收藏

页数：2

相关论文

共 3 条

[1] Longitudinal Analysis of BCVA and Near-Field Object Recognition in Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b/3 Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE)
Barone, Samuel
MOLECULAR THERAPY, 2024, 32 (04) : 451 - 451
[2] Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)
Boyer, David
Bergstrom, Lance
Emanuelli, Andres
Gonzalez, Victor
Wykoff, Charles
Gupta, Sunil
Liao, David
Zak, Vitaliy
Chavala, Sai
Mohanty, Samar
Bataybal, Subrata
Piltz-Seymour, Jody
Ayyagari, Ananta
Koester, John
Osborne, Aaron
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[3] Longitudinal BCVAAnalysis of Patients With Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT)
Mahajan, Vinit B.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)